共 50 条
- [1] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trialLANCET ONCOLOGY, 2021, 22 (06): : 872 - 882Yu, Evan Y.Petrylak, Daniel P.O'Donnell, Peter H.Lee, Jae-Lyunvan der Heijden, Michiel S.Loriot, YohannStein, Mark N.Necchi, AndreaKojima, TakahiroHarrison, Michael R.Park, Se HoonQuinn, David, IHeath, Elisabeth, IRosenberg, Jonathan E.Steinberg, JoyceLiang, Shang-YingTrowbridge, JanetCampbell, MaryMcGregor, BradleyBalar, Arjun, V
- [2] Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case seriesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Martini, Dylan J.Lalani, Aly-Khan A.Bosse, DominickSteinharter, John A.Harshman, Lauren C.Hodi, F. StephenOtt, Patrick A.Choueiri, Toni K.
- [3] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial (vol 22, pg 872, 2021)LANCET ONCOLOGY, 2021, 22 (06): : E239 - E239Yu, E. Y.Petrylak, D. P.O'Donnell, P. H.
- [4] Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II StudyCLINICAL CANCER RESEARCH, 2022, 28 (11) : 2321 - 2328Jung, Hyun AePark, SehhoonChoi, Yoon-LaLee, Se-HoonAhn, Jin SeokAhn, Myung-JuSun, Jong-Mu
- [5] Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyJAMA ONCOLOGY, 2018, 4 (11) : 1543 - 1552Ferrara, RobertoMezquita, LauraTexier, MatthieuLahmar, JiheneAudigier-Valette, ClarisseTessonnier, LaurentMazieres, JulienZalcman, GerardBrosseau, SolennLe Moulec, SylvestreLeroy, LauraDuchemann, BorisLefebvre, CorentinVeillon, RemiWesteel, VirginieKoscielny, SergeChampiat, StephaneFerte, CharlesPlanchard, DavidRemon, JordiBoucher, Marie-EveGazzah, AnasAdam, JulienBria, EmilioTortora, GiampaoloSoria, Jean-CharlesBesse, BenjaminCaramella, Caroline
- [6] The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapyONCOIMMUNOLOGY, 2022, 11 (01):Huang, JiweiSu, RuopengChen, ZeyuJiang, ShuaiChen, MinfengYuan, YichuHu, HailongFu, ChangdeHuang, ZhiyangWang, ZhenyuZheng, BingLi, ChancanWang, ZaoyuBao, YigeCai, MingGuo, JianmingWei, QiangXue, Wei
- [7] Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trialANNALS OF ONCOLOGY, 2022, 33 : S240 - S240Shitara, K.Golan, T.Mileham, K.Voskoboynik, M.Rha, S.Gutierrez, M.Perets, R.Taylor, S.Chen, D.Keenan, T.Rajasagi, M.Healy, J.Shoji, H.
- [8] First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Wei, Xiao X.Lundgren, KevinTeo, Min YuenRosenberg, Jonathan E.Koshkin, Vadim S.Grivas, PetrosCarril, LuciaCastellano, Daniel E.Velho, PedroHahn, Noah M.McKay, Rana R.Raggi, DanieleNecchi, AndreaKanesvaran, RaviAlerasool, ParissaGaines, JacobMorrison, LauraPowles, ThomasBellmunt, JoaquimSonpavde, Guru
- [9] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Lee, Chung-HanShah, Amishi YogeshHsieh, James J.Rao, ArpitPinto, AlvaroBilen, Mehmet AsimCohn, Allen LeeDi Simone, ChristopherShaffer, David R.Sarrio, Regina GironesRibe, Sara GunnestadWu, JaneSchmidt, Emmett, VPerini, Rodolfo F.Kubiak, PeterSmith, Alan D.Motzer, Robert J.
- [10] Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) "platinum-ineligible" patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practiceANNALS OF ONCOLOGY, 2022, 33 : S1490 - S1490Molina Cerrillo, J.Ortego, I.Pinto Marin, A.Alonso Gordoa, T.Puente, J.Arranz Arija, J. A.Lopez Criado, M. P.Gonzalez Morales, A.Vidal Cassinello, N.Castellano Gauna, D. E.Sevillano Fernandez, E.Garcia Donas, J.Grande Pulido, E.